Cervical Cancer Diagnostic Market to Grow with a CAGR of 5.60% through 2028
Advances in technology, government-led initiatives,
and a shift towards preventive healthcare is expected to drive the Global Cervical
Cancer Diagnostic Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “Cervical
Cancer Diagnostic Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Cervical
Cancer Diagnostic Market stood at USD 7.50 billion in 2022 and is anticipated
to grow with a CAGR of 5.60% in the forecast period, 2024-2028. This can be
attributed to government-led screening initiatives. Many governments and health
organizations have launched national screening programs to reach underserved
populations. These initiatives typically offer free or low-cost screenings,
ensuring that a broader cross-section of women can access diagnostic services.
Such programs have had a significant impact on increasing the number of women
being screened, thus boosting the market's growth.
Furthermore, Point-of-care testing is a significant
trend in cervical cancer diagnostics. Portable and rapid diagnostic devices are
being developed, allowing for real-time testing and immediate results. These
POCT devices are especially beneficial in underserved and remote areas, where
access to traditional laboratory facilities is limited.
Cervical cancer originates in the cervix of the uterus
in women, where abnormal cell growth can evolve into cancerous cells.
Diagnostic tests for cervical cancer are designed to identify early signs of
precancerous changes in cells and tissues, facilitating more effective
treatment. Early detection greatly enhances the success of cervical cancer
treatment. Even in more advanced stages, it can still be managed with
appropriate care. After the age of 30, it's recommended that women undergo
regular pap smears and liquid-based cytology tests, including HPV screening.
Lifestyle factors also play a significant role in
cervical cancer risk. Women with unhealthy habits are more susceptible to this
disease. Lifestyle elements such as smoking, oral contraceptive use, and
inadequate genital hygiene can elevate the likelihood of cervical cancer,
serving as driving forces for market growth. According to the National
Institute of Health (NIH), obesity is another significant factor affecting
cervical cancer risk in women. Obese women face a higher risk compared to those
with a healthy weight. Additionally, early menstruation and late menopause,
which affect hormonal conditions and reproductive health, can contribute to
cervical cancer. The disease can be transmitted through sexual contact due to
HPV infection, and having multiple sexual partners can increase the risk.
The COVID-19 pandemic had a substantial impact on the
market, disrupting global supply chains and causing shortages of screening
products. However, post-pandemic, there has been an increasing demand for
cervical cancer diagnostic products due to the prevalence of the disease.
Government initiatives for cervical cancer detection
and treatment, as well as rising awareness about the disease, have led to the
greater adoption of screening procedures like pap tests and HPV testing. The
presence of favorable reimbursement policies is expected to boost the number of
screening tests in the coming years. Technological advancements in diagnostic
equipment, procedures, and screening techniques are anticipated to have a
positive impact on the market. Thus, technology stands as a key driver for
industry growth.
Developing countries are anticipated to make
significant contributions to the market due to increased research and
development efforts and the growth of biotechnological industries. The rising
awareness of the importance of cervical cancer screening techniques is a
driving force behind market expansion.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Cervical Cancer Diagnostic Market.”
The Global Cervical Cancer Diagnostic Market is
segmented into test type, end user, regional distribution, and company.
Based on its test type, the Pap testing segment took
the lead in market share, followed by HPV testing. Pap tests are instrumental
in the early detection of cervical cancer, even before any symptoms manifest.
Early discovery of cervical cancer through Pap tests significantly enhances
treatment efficacy, which contributes to the widespread popularity of this
testing method.
Looking ahead to the forecast period from 2023 to
2030, the HPV testing segment is poised for the most rapid growth due to the
increasing number of individuals affected by HPV. HPV testing plays a pivotal
role in identifying the Human Papilloma Virus, a primary factor in the
development of cervical cancer. Detecting the presence of HPV can also serve as
an indicator for the onset of cervical cancer.
Based on end user, the diagnostic laboratories sector
secured a significant portion of the market share in 2022, primarily owing to
the abundance of service choices and equipment available in diagnostic
facilities. Consequently, patients exhibited a preference for diagnostic
laboratories over hospitals.
Forecasts indicate that the diagnostic laboratories
sector is poised for rapid growth and will continue to maintain its leading
position throughout the projected period. The emergence of the COVID-19
pandemic prompted the diagnostic market to engage more directly with consumers.
People began placing greater emphasis on preventive measures, which in turn
elevated the demand for testing. With the added convenience of at-home testing,
the home diagnostics sector is expected to witness a surge in activity during
the forecasted timeframe.
Major companies operating in Global Cervical
Cancer Diagnostic Market are:
- Abbott Laboratories Inc
- Thermo Fisher Scientific Inc
- Becton Dickinson & Co
- Hologic Inc
- CooperSurgical Inc
- Siemens Healthineers AG
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The global cervical cancer diagnostic market is
witnessing significant trends that are poised to shape the future of cervical
cancer screening and early detection. From the adoption of molecular
diagnostics and AI integration to the emphasis on personalized medicine and
telemedicine, these trends are helping to drive progress in the fight against
cervical cancer. As technology and research continue to evolve, the diagnostic
market will play a crucial role in reducing the global burden of this
preventable disease,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Cervical Cancer Diagnostic Market By
Test Type (Pap testing, HPV testing, Colposcopy,
Cervical biopsies, Cystoscopy), By End User (Hospitals & Clinics,
Diagnostic Laboratories, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Cervical Cancer Diagnostic Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Cervical Cancer Diagnostic Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com